首页> 外文OA文献 >Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

【2h】

Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

机译：综合同期研究的综合结果与SHER2 / NEU B细胞肽疫苗与顺铂和5-氟尿嘧啶或Capecitabine化疗，表现出Her2 / Neu过表达晚期胃癌患者的安全性，免疫原性和临床反应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
U. Wiedermann; E. Garner-Spitzer; Y. Chao; I. Bulat; A. Dechaphunkul; W. Arpornwirat; C. Charoentum; C.J. Yen; T. Yau; M. Maglakelidzde; S. Tanasanvimon; J. Maneechavakajorn; A. Sookprasert; L.-Y. Bai; W.-C. Chou; T. Ungtrakul; C.C. Zielinski; L. Chong; N. Ede; A. Good;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. 2129 POSTER An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2–) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC [J] . D.Tripathy, C.Moisa, S.Glück European Journal of Cancer Supplements . 2007,第4期

机译：2129海报公开了一项卡培他滨（C）和多西他赛（D）作为新辅助治疗新确诊的HER2-neu阴性（HER2-–）乳腺癌（BC）加上曲妥珠单抗（T）HER2-neu阳性（HER2 +）的患者的开放性研究）
2. Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naive Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial [J] . Kawakami Hisato, Takeno Atsushi, Endo Shunji, The oncologist . 2018,第12期

机译：随机的，开放标签期II研究将Capecitabine-Cisplatin每3周与S-1-Cisplatin进行比较，每5周在化疗 - 天真患者2阴性晚期胃癌患者中每隔5周：OGSG1105，Herbis-4a试验
3. Randomized prospective phase ii study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer [J] . OcvirkJ., Reber?ekM., ?kofE., American Journal of Clinical Oncology: Cancer Clinical Trials . 2012,第3期

机译：前瞻性ii期随机研究比较了表柔比星，顺铂和5-氟尿嘧啶与表柔比星，顺铂和卡培他滨联合化疗方案在晚期或转移性胃癌患者中的作用
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. Randomized Open‐Label Phase II Study Comparing Capecitabine‐Cisplatin Every 3 Weeks with S‐1‐Cisplatin Every 5 Weeks in Chemotherapy‐Naïve Patients with HER2‐Negative Advanced Gastric Cancer: OGSG1105 HERBIS‐4A Trial [O] . Hisato Kawakami, *, Atsushi Takeno, 2018

机译：随机开放标签II期研究比较了未经化疗的HER2阴性晚期胃癌患者每3周将卡培他滨-顺铂与S-1-顺铂每5周进行一次的比较：OGSG1105HERBIS-4A试验
6. Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine [O] . 2014

机译：ae37 + gm-csf her2肽疫苗II期试验中HER2 / neu抗体反应与临床反应的相关性
7. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide- Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy; Annual rept. 27 Apr 2007-26 Apr 2008 [R] . Disis, M. L. 2008

机译：对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu（HER2）细胞内结构域（ICD）基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日

Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

著录项

引文网络

相似文献

相关主题

期刊订阅